Clinical Colorectal Cancer
Papers 1167
1 page of 117 pages (1,167 results)
#1Masayuki Nakashima (Kyoto University)
#2Masato Takeuchi (Kyoto University)H-Index: 3
Last. Koji Kawakami (Kyoto University)H-Index: 27
view all 3 authors...
Abstract Introduction/background Compared to the best supportive care, a survival benefit of using regorafenib and trifluridine/tipiracil (TFTD) in colorectal cancer patients has been shown in previous randomized controlled trials (RCT). However, there is no RCT or large-scale observational study directly comparing regorafenib and TFTD. Patients and methods We used a nationwide claims database in Japan and compared the effectiveness of regorafenib and TFTD for metastatic colorectal cancer during...
#1Emil Lou (UMN: University of Minnesota)H-Index: 19
#2Subbaya Subramanian (UMN: University of Minnesota)H-Index: 39
#1Marta SchirripaH-Index: 15
#2F Nappo (UNIPD: University of Padua)
Last. Giovanni FucàH-Index: 8
view all 16 authors...
Abstract Background KRAS G12C mutation occurs in about 4% of colorectal cancers (CRCs). Recently, KRAS G12C was identified to be potentially druggable and predictor of response to the novel on AMG510 target treatment. The present work aims to describe clinical-pathological features and prognosis of KRAS G12C mutated metastatic CRCs, compared to other KRAS mutation. Methods Clinico pathological features and outcome data of KRAS mutated metastatic (m)CRC patients referred to three Italian Oncology...
ABSTRACT In this retrospective analysis of 83 patients with high levels of baseline CEA, who received the first-line chemotherapy, two CEA kinetics-related variables after 8 weeks were evaluable prognostic factors, in particular for patients with right-sided tumors. Background Carcinoembryonic antigen (CEA) best reduction after chemotherapy in patients with metastatic colorectal cancer (mCRC) has been reported as a prognostic factor. The study aims to evaluate whether serum CEA kinetics after 8 ...
#1Matthew Henry (WSU: Wayne State University)
#2Nina Delavari (DMC: Detroit Medical Center)
Last. John Webber (DMC: Detroit Medical Center)
view all 3 authors...
Abstract Colorectal cancer is third most common cancer in the United States. Adenocarcinoma is the most common type of large intestine cancer. Signet ring cell adenocarcinoma (SRCC), a subtype of adenocarcinoma, is characterized by the tumor cells production of intracellular mucin. SRCC has several unique characteristics: it more commonly presents in younger patients, is located in the right hemi-colon or rectum, invades the lymphatic system, and metastasizes to the peritoneum. We describe the c...
#2Cristina GrávalosH-Index: 15
Last. Enrique Aranda (UCO: University of Córdoba (Spain))H-Index: 28
view all 10 authors...
ABSTRACT Colorectal cancer (CRC) is a public health problem: it is the 3rd most common cancer in men (746,000 new cases/year) and the 2nd in women (614,000 new cases/year), representing the second cause of death by cancer worldwide. The survival of patients with metastatic CRC (mCRC) has increased prominently in recent years reaching a median of 25-30 months. A growing number of patients with mCRC are candidates to receive a treatment in third-line or beyond, although the optimal drug regimen an...
Background Because more than one neoadjuvant treatment is available for advanced rectal cancer, the aim of this study was to compare the differential clinical and pathologic effects of different combinations of chemoradiation regimens, treatment sequencing, and timing to surgery on patient outcomes Patients and Methods Between January 2015 and October 2018, 126 newly diagnosed rectal cancer patients with MRI-based cT3-4 or N+ rectal disease for curative-intent treatment received one of 4 neoadju...
Background NCCN guidelines for the treatment of locally advanced rectal cancer (LARC) advocate neoadjuvant chemoradiation (NA-CRT) followed by total mesorectal excision (TME) and adjuvant chemotherapy (AC). The aim of this retrospective study was to determine our local patterns of AC use and examine factors that influenced initiation and completion of AC among patients with stage II/III rectal cancer. Methods The study population consisted of stage II/III rectal cancer patients that were treated...
Top fields of study
Colorectal cancer
General surgery